| Latest | F'cast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | n/a | n/a |
| ROCE | n/a |
| Latest | F'cast | |
|---|---|---|
| P/E | n/a | n/a |
| PEG | n/a | n/a |
| Pr/Revenue | n/a | n/a |
| Pr/Book | 8.6 |
| Latest | F'cast | |
|---|---|---|
| Revenue | n/a | n/a |
| PBT | n/a | n/a |
| EPS | n/a | n/a |
| DPS | n/a | n/a |
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 30-Jun-08 | n/a | (2.47) | (9.92)p | n/a | n/a | n/a | n/a | 0.0% |
| 30-Jun-09 | n/a | (2.84) | (10.64)p | n/a | n/a | n/a | n/a | 0.0% |
| 30-Jun-10 | n/a | (2.92) | (4.27)p | n/a | n/a | n/a | n/a | 0.0% |
| 30-Jun-11 | 0.15 | (3.66) | (5.37)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-11 | n/a | (2.22) | (5.61)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 30-Jun-12 | n/a | (3.80) | (5.00)p | n/a | n/a | n/a | n/a | 0.0% |
| 30-Jun-13 | n/a | (2.40) | (3.00)p | n/a | n/a | n/a | n/a | 0.0% |
Copyright © 2012 FactSet Research Systems Inc. All rights reserved.
| Professor Stephen Holgate given prestigious Award | 22-May-2012 | 07:30 | RNS |
| Holding(s) in Company | 01-May-2012 | 12:55 | RNS |
| Positive Phase II asthma data | 19-Apr-2012 | 07:00 | RNS |
| Synairgen no wheeze as asthma drug trial boosts ... | 19-Apr-2012 | ShareCast |
| Takeover targets named | 29-Jan-2011 | ShareCast |
| Small caps round-up: Plantic Technologies, Acal,... | 29-Jul-2010 | ShareCast |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 38.50p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 52.00p |
| 52 Week Low | 17.50p |
| Volume | 3,636 |
| Shares Issued | 69.56m |
| Market Cap | £26.78m |
| Beta | 0.33 |
| RiskGrade | 343 |
| Value | ![]() |
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| No dividends found |
| CEO | Richard J Marsden |
| Finance Director | John C Ward |
You are here: research